Panacea Biotec
NSE: PANACEABIO · Pharmaceuticals
Snapshot
Unlock Panacea Biotec's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Panacea Biotec is an Indian biotechnology firm focused on the research, development, and manufacturing of pharmaceuticals, vaccines, and biosimilars. The company operates through two primary segments: Vaccines and Formulations, serving both domestic and international markets.
Business Model
The company generates revenue by marketing prescription pharmaceutical products across various therapeutic areas and supplying vaccines globally. It leverages strategic collaborations with international research organisations and investment funds to develop and manufacture specialised vaccine candidates.
- Export Presence:Over 30 countries
Growth Outlook
Growth is driven by the development of next-generation vaccine candidates targeting SARS-CoV-2 variants and other Beta coronaviruses. Continued expansion of its global footprint and product portfolio in therapeutic areas like oncology and diabetes remains a key focus.
- Key Partnerships:Russian Direct Investment Fund, CEPI, THSTI
Key Risks
- Regulatory Risk. The company faces stringent regulatory oversight in international markets, which could impact the approval and commercialisation of its pharmaceutical and vaccine products.
- R&D Failure Risk. As a biotechnology company, significant capital is invested in research and development, where failure to achieve clinical trial success can adversely affect financial performance.
- Geopolitical Risk. Operations and export activities in diverse regions, including the Russian Federation, expose the company to potential geopolitical instability and trade sanctions.
- Market Competition. The pharmaceutical and vaccine sectors are highly competitive, requiring continuous innovation to maintain market share against established global players.
Start your research today
Unlock AI insights, financials, peers and live data on Panacea Biotec and 5,000+ companies — free.
Key Metrics
REVENUE
₹673 Cr
TTM · consolidated
NET PROFIT
₹-9 Cr
TTM · consolidated
EPS
₹-1.16
TTM · consolidated
RETURN ON EQUITY
-1.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
-0.4%
TTM · consolidated
P/E
-328.7x
Q1 FY27 · consolidated
EV/EBITDA
130.3x
Q1 FY27 · consolidated
EBITDA MARGIN
2.6%
TTM · consolidated
NET PROFIT MARGIN
1.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Panacea BiotecPANACEABIO | ₹2,335 Cr | -328.66 | 130.32 | 10.3% | 2.6% | -1.1% | -0.4% | -6.4% |
Windlas BiotechWINDLAS | ₹2,377 Cr | 35.61 | 19.64 | 18.5% | 13.0% | 12.2% | 16.8% | +14.5% |
Sai Parenterals LimitedSAIPARENT | ₹2,295 Cr | — | — | — | 10.0% | — | — | — |
Shukra Pharmaceuticals LimitedSHUKRAPHAR | ₹2,283 Cr | — | — | — | 51.0% | — | — | +83.1% |
Venus RemediesVENUSREM | ₹2,265 Cr | 19.50 | 12.59 | 20.9% | 21.9% | 19.0% | 23.9% | +265.3% |
Sakar HealthcareSAKAR | ₹2,256 Cr | 62.59 | 28.58 | 43.8% | 29.7% | 11.8% | 15.6% | +197.4% |
As of Q1 FY27
Financials
Panacea Biotec
NSE: PANACEABIO · Pharmaceuticals
Snapshot
Unlock Panacea Biotec's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Panacea Biotec is an Indian biotechnology firm focused on the research, development, and manufacturing of pharmaceuticals, vaccines, and biosimilars. The company operates through two primary segments: Vaccines and Formulations, serving both domestic and international markets.
Business Model
The company generates revenue by marketing prescription pharmaceutical products across various therapeutic areas and supplying vaccines globally. It leverages strategic collaborations with international research organisations and investment funds to develop and manufacture specialised vaccine candidates.
- Export Presence:Over 30 countries
Growth Outlook
Growth is driven by the development of next-generation vaccine candidates targeting SARS-CoV-2 variants and other Beta coronaviruses. Continued expansion of its global footprint and product portfolio in therapeutic areas like oncology and diabetes remains a key focus.
- Key Partnerships:Russian Direct Investment Fund, CEPI, THSTI
Key Risks
- Regulatory Risk. The company faces stringent regulatory oversight in international markets, which could impact the approval and commercialisation of its pharmaceutical and vaccine products.
- R&D Failure Risk. As a biotechnology company, significant capital is invested in research and development, where failure to achieve clinical trial success can adversely affect financial performance.
- Geopolitical Risk. Operations and export activities in diverse regions, including the Russian Federation, expose the company to potential geopolitical instability and trade sanctions.
- Market Competition. The pharmaceutical and vaccine sectors are highly competitive, requiring continuous innovation to maintain market share against established global players.
Start your research today
Unlock AI insights, financials, peers and live data on Panacea Biotec and 5,000+ companies — free.
Key Metrics
REVENUE
₹673 Cr
TTM · consolidated
NET PROFIT
₹-9 Cr
TTM · consolidated
EPS
₹-1.16
TTM · consolidated
RETURN ON EQUITY
-1.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
-0.4%
TTM · consolidated
P/E
-328.7x
Q1 FY27 · consolidated
EV/EBITDA
130.3x
Q1 FY27 · consolidated
EBITDA MARGIN
2.6%
TTM · consolidated
NET PROFIT MARGIN
1.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27